Risultati per: Progressi nel trattamento della psoriasi: review

Circulation, Volume 150, Issue Suppl_1, Page A4142116-A4142116, November 12, 2024. Introduction:The measurement of Urinary Sodium Concentration (UNa) is a pivotal biomarker in managing Acute Heart Failure (AHF), offering a non-invasive and readily accessible means to evaluate diuretic response. This systematic review and meta-analysis is designed to investigate the correlation between UNa levels and patient-centric outcomes in AHF, aiming to validate the evidence base and refine clinical practice.Methods:This systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. We systematically searched PubMed, Cochrane Central, Scopus, Google Scholar, and ClinicalTrials.gov from their inception to May 2024. Our search included randomized controlled trials (RCTs) and observational studies comparing outcomes between acute heart failure (AHF) patients with high urinary sodium concentration (UNa) and those with low UNa.Results:The analysis included 12 studies comprising 5 RCTs and 7 observational studies, incorporating a total of 8,743 AHF patients. In the high UNa group, pooled data demonstrated significantly higher urinary output (MD 534.49 ml, 95% CI 348.48 to 720.49; P < 0.00001) and increased weight loss (MD 1.15 kg, 95% CI 0.45 to 1.85; P < 0.001). Additionally, there was a lower risk of renal function decline (OR 0.48, 95% CI 0.24 to 0.97; P < 0.04). Patients with high urinary sodium had a shorter mean hospital stay of 7.6 days compared to 8.8 days for those with low UNa, with an overall reduction in length of stay (MD -1.38 days, 95% CI -2.44 to -0.32; P < 0.01). Mortality was also lower in the high UNa group, particularly over longer follow-up periods: at 1-month follow-up (OR 0.40, 95% CI 0.21 to 0.78; P = 0.007), at 6-month follow-up (OR 0.45, 95% CI 0.29 to 0.72; P = 0.0007), and at 12-month follow-up (OR 0.16, 95% CI 0.16 to 0.26; P < 0.00001). Furthermore, the high UNa group exhibited a lower risk of worsening heart failure requiring inotropes (OR 0.40, 95% CI 0.23 to 0.70; P = 0.002) and a reduced incidence of heart failure rehospitalization (OR 0.42, 95% CI 0.20 to 0.89; P = 0.02).Conclusion:High urinary sodium concentration is strongly associated with improved clinical outcomes in acute heart failure, including greater urinary output, increased weight loss, shorter hospital stays, and reduced risks of renal function decline, mortality, worsening heart failure, and rehospitalization.

Circulation, Volume 150, Issue Suppl_1, Page A4145057-A4145057, November 12, 2024. Introduction:Cardiovascular Implantable Electronic Device (CIED) infection is class I indication for complete transvenous lead removal (LR). The reimplantation strategies post-LR, especially in pacemaker-dependent patients or those necessitating cardiac resynchronization therapy (CRT) and/or implantable defibrillators, remain complex. Considering the limitations and risks associated with traditional approaches, the exploration of alternative devices such as leadless pacemakers (LP) have garnered attention due to their purported lower infection risk.Methods:We meticulously reviewed literature sources including PubMed, Scopus, and Embase utilizing a combination of search terms. The inclusion criterion was LP implantation post-LR of infected CIED, while the exclusion criterion was LR for noninfectious indications. Study endpoints encompassed patients’ outcomes during follow-up.Results:Our literature review yielded 818 articles, of which 21 met the inclusion criteria, encompassing a cohort of 612 patients who underwent LR followed by LP implantation (Table 1). A total of 250 (40.8%) patients underwent concurrent LP implantation during the LR procedure. The rest underwent staged procedures and the overall duration between LR of infected CIED and LP implantation was 4.32 ± 3.9 days. In our cohort, 172 (28.1%) patients had systemic CIED infections, whereas 130 (21.2%) had isolated pocket infections, with Staphylococcus aureus as the predominant causative organism in 96 (39.3%) cases. Procedural complications were scarce. Over a mean follow-up period of 13.2 ± 8.1 months, pacemaker syndrome was observed in 3 (0.67%) patients, while 1 (0.16%) patient had a re-infection related to LP.Conclusion:The remarkably low incidence of complications and re-infections following LP implantation underscores its potential utility as a viable implantation option after LR, particularly in pacing-dependent patients at higher risk of CIED infections.

Circulation, Volume 150, Issue Suppl_1, Page A4142193-A4142193, November 12, 2024. INTRODUCTION:Many anti-cancer agents, including alkylating, anthracycline-based, and anti-HER2 chemotherapies, have a high risk of causing clinically significant cardiac toxicity, manifesting as heart failure (HF). The efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i’s) in HFrEF and HFpEF is well-established; their role, however, in managing chemotherapy-related cardiac dysfunction (CTRCD) remains unclear.AIMS:To analyze available data on the efficacy of SGLT2i’s in CTRCD.Methods:Pubmed, Embase and Web of Science databases were queried to find relevant clinical studies on the use of SGLT2i’s in CTRCD. Primary outcomes included HF incidence, HF exacerbations, and all-cause mortality. Using a random effects model, relative risk ratios (RRs) with 95% confidence intervals were computed for all outcomes.Results:Out of 807 retrieved citations, 4 observational studies with 6576 participants were included in the analysis. In SGLT2i’s and non-SGLT2i’s groups, the number of subjects, mean age, and proportion of males were 1551 vs. 5025, 67.6 vs. 68.9 years, and 42% (648) vs. 40% (2000) with median follow-up range of 1.5-3.4 years. Only one study enrolled patients with prior HF, while diabetes was common among all. Anthracyclines were the most common chemotherapy agents used and the majority of patients had a hematological malignany. Onset of HF in the SGLT2i’s group, as reported by two studies, was 6/31 and 94/930 in the non-SGLT2is group. The pooled HF incidence rate was similar between the two groups, with an RR of 0.54 (0.25-1.16, p=0.11). SGLT2i’s users had a significantly lower rate of HF exacerbations and all-cause mortality compared with those who did not receive SGLT2i’s with RR of 0.54 (0.33-0.91, p=0.02) and 0.48 (0.32-0.73, p=0.0006), respectively. Additionally, SGLT2i’s were associated with a significantly lower rate of arrhythmias [ RR 0.40 (0.22-0.70, p=0.001)]. The mortality effect was beleived to be influenced by the antitumor effects of SGLT2i’s as well. Moreover, the rates of adverse events secondary to SGLT2i’s, such as euglycemic ketoacidosis, hypoglycemia, and infections, were reported to be lower.Conclusion:The observational data on the efficacy of SGLT2i’s in CTRCD are promising. These drugs were found to have favorable effects on HF exacerbations, all-cause mortality, and arrhythmias onset associated with CTRCD. Large-scale randomized clinical trials are needed to validate these findings.

Circulation, Volume 150, Issue Suppl_1, Page A4148117-A4148117, November 12, 2024. Background:Tricuspid regurgitation (TR) is a prevalent disease in the population and is usually progressive. Most patients are treated with conservative management due to the risk involving transcatheter tricuspid valve replacement (TTVR) and surgical tricuspid valve replacement (STVR). The TRI-SCORE was developed to evaluate the severity of patients with TR and their risk of undergoing a correction procedure. However, there is still controversy regarding the cutoff value of the score. Therefore, we aim to perform a systematic review and meta-analysis comparing the cutoffs ≥6 with =6 with

Circulation, Volume 150, Issue Suppl_1, Page A4148133-A4148133, November 12, 2024. Background:Left ventricular assist devices (LVADs) are crucial for the management of advanced heart failure patients acting, both as a bridge to heart transplant or destination therapy. Existing studies revealed mixed results on the impact of pre-implant left ventricular end-diastolic diameter (LVEDD) on post-LVAD mortality. Some studies found smaller LVEDD increases mortality, while others revealed no significant impact. Due to the limited evidence, this meta-analysis aims to determine the association between pre-LVEDD and post-LVAD implantation mortality through a systematic review and meta-analysis.Method:We systematically reviewed articles until May 2024 examining the association between pre-implant LVEDD and post-LVAD implantation mortality using PubMed, Google Scholar, Embase, and Scopus. A random effects model was used to calculate the pooled adjusted odds ratio (aOR). We used I2statistics to determine the heterogeneity of studies. Leave-one-out sensitivity analysis was done to evaluate each study’s effect on the overall estimate, with statistical significance set at p

Circulation, Volume 150, Issue Suppl_1, Page A4136033-A4136033, November 12, 2024. Background:Folic acid, a B vitamin, is essential for DNA synthesis and repair, and its role in reducing homocysteine levels has been linked to cardiovascular health. Elevated homocysteine is a risk factor for cardiovascular diseases, including acute myocardial infarction (MI) and coronary artery disease (CAD). Despite evidence suggesting that folic acid supplementation may lower homocysteine levels, its clinical benefits in reducing cardiovascular events remain unclear.Methods:A comprehensive literature search was conducted in PubMed/Medline, Google Scholar, and Cochrane Library databases for studies published from 2000 to 2024 using MeSH terms related to “folic acid,” “B vitamin,” “acute myocardial infarction,” “cardiac arrest,” “heart attack,” and “coronary heart disease.” Only randomized controlled trials (RCTs) and observational studies in English involving adult patients with acute MI or CAD were included. Exclusion criteria were applied to poor-quality studies, irrelevant outcomes, overlapping populations, and non-English texts. Data on study characteristics and patient demographics were extracted, and study quality was assessed using the RoB2 tool. Outcomes were pooled using RevMan 5.3.4 software.Results:Fourteen studies on all-cause mortality showed a risk ratio (RR) of 0.99 [95% CI: 0.94-1.04], indicating no significant difference between folic acid and control groups. Eight studies on cardiovascular mortality yielded a RR of 0.90 [95% CI: 0.82-0.99], suggesting a significant reduction in cardiovascular deaths with folic acid supplementation. Analyses of sudden death, coronary artery bypass graft (CABG) events, revascularization procedures, stroke, and recurrent MI found no significant associations with folic acid supplementation.Conclusions:High-dose folic acid supplementation appears to reduce cardiovascular mortality in post-MI patients but shows no significant impact on other clinical outcomes. This meta-analysis’s limitations include potential publication bias, heterogeneity among included studies, and variability in folic acid dosages and treatment durations. Furthermore, the lack of comprehensive homocysteine level data constrained the analysis. Future large-scale RCTs are needed to fully ascertain the therapeutic potential of folic acid supplementation in secondary prevention of cardiovascular events.

Circulation, Volume 150, Issue Suppl_1, Page A4144695-A4144695, November 12, 2024. Background:The favorable safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors, notably empagliflozin and dapagliflozin, make them a suitable treatment option for type 2 diabetes mellitus (T2DM). However, their comparative efficacy and cardiovascular (CV) benefits still remain unclear. This meta-analysis aims to compare the CV outcomes between Dapagliflozin and Empagliflozin in T2DM patients, exploring their varying effectiveness.Methods:A comprehensive search of electronic databases, PubMed, Embase, and Google Scholar was conducted from inception till May 2024. The study was conducted adhering to the PRISMA guidelines. Following a thorough screening and quality assessment, primary outcomes including major adverse cardiovascular events (MACE), cardiovascular (CV) mortality, and all-cause death along with secondary outcomes including stroke, myocardial infarction (MI), and heart failure (HF), were extracted. The random effects model was used to pool the odds ratio (OR) along with the corresponding 95% confidence intervals (CIs) for all outcomes. A p-value of less than 0.05 was considered statistically significant.Results:We pooled 6 studies with a total of 172,293 participants. The evaluation of pool results showed a significant association between the use of empagliflozin and dapagliflozin for reducing CV mortality (OR 1.15, 95 % CI 1.01- 1.30; p=0.04) and MACE (OR 1.15, 95 % CI 1.01- 1.30; p=0.04). However, we found no statistically significant difference between the two drugs for reducing MI (OR 1.04, 95 % CI 0.90- 1.19; p=0.59), Stroke (OR 0.92, 95 % CI 0.76- 1.11; p=0.40), HF (OR 1.30, 95 % CI 0.93- 1.81; p=0.13) and all-cause death (OR 1.33, 95 % CI 0.46- 3.88; p=0.60). After running the sensitivity analysis, a statistically significant result was observed between use of empagliflozin and dapagliflozin for HF (OR 1.47, 95 % CI 1.13- 1.90; p=0.004).Conclusion:The use of dapagliflozin significantly reduces CV mortality and MACE when compared with empagliflozin. However, the incidence of MI, stroke, HF, and all-cause death is comparable across the two groups. Our results should be considered hypothesis generating and evidence from large-scale multi-centric randomized controlled trials (RCTs) is required to reach a definitive conclusion

Circulation, Volume 150, Issue Suppl_1, Page A4146753-A4146753, November 12, 2024. Background:The role of digital health interventions (DHI) in addition to usual care (UC) in patients discharged after an acute coronary syndrome (ACS) remains uncertain.Hypothesis:DHI improves medication adherence, and systolic blood pressure (BP) control and reduces mortality in patients after an ACS.Purpose:To ascertain the efficacy of adding DHI to UC in patients discharged after an ACS through a systematic review and meta-analysis.Methods:We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing DHI plus UC versus UC alone in patients discharged after an ACS. We pooled risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) for binary and continuous outcomes, respectively. Our outcomes of interest were medication adherence (as per the studies’ definitions), all-cause mortality, and systolic BP. Statistical analyses were performed using R software version 4.4.0.Results:We included 22 RCTs comprising 20,587 patients, of whom 14,079 (68.4%) were randomized to DHI + UC. The mean age was 59.5 years and 58.5% were male. About 15% had diabetes mellitus at baseline while 54% had hypertension. In the pooled analysis, DHI plus UC significantly increased medication adherence (RR 1.06; 95% CI 1.01 to 1.13; p=0.03; Fig. 1) and reduced systolic BP (MD -3.16 mmHg; 95% CI -5.53 to -0.79; p

Circulation, Volume 150, Issue Suppl_1, Page A4144752-A4144752, November 12, 2024. Background:Adults with congenital heart disease (ACHD) are lifelong at high risk for premature cardiovascular events and life-threatening complications, suggestive of early or accelerated cardiovascular disease. Endothelial and microvascular dysfunction as well as arterial stiffness play a key role in the emergence and progression of cardiovascular complications. As vascular dysfunction may precede the occurrence of adverse events, early identification of endothelial damage markers in ACHD is crucial.Aim:This is the first systematic review and meta-analysis of studies investigating the endothelial and microvascular function in ACHD patients versus healthy controls.Methods:We systematically searched four major electronic databases (PubMed, CENTRAL, Scopus, Web of Science), ClinicalTrials.gov and grey literature. We included studies evaluating endothelial and microvascular function with any semi- or non-invasive method in adult patients with and without ACHD. Studies exploring arterial stiffness indices were also investigated.Results:In total, 31 studies (1118 ACHD patients, 794 controls) were included in this systematic review. Branchial arterial endothelium-dependent (assessed via flow-mediated dilatation, FMD) and -independent vasodilation (assessed via nitroglycerine-mediated dilatation, NMD) were impaired in ACHD patients versus controls (mean difference [MD] -2.5, 95% confidence intervals [CI] -3.7; -1.3 and MD -3.9, 95%CI -6.8; -1.0, respectively). Microvascular dysfunction was also evident; significantly lower reactive hyperemia index and peripheral arterial tonometry (PAT) ratio were found in ACHD patients compared with controls (MD −0.26, 95%CI −0.48; −0.04 and MD −0.26, 95%CI −0.5; −0.4, respectively). Regarding arterial stiffness, pooled analysis revealed non-significant differences in pulse wave velocity between the study groups (standardized MD 0.2, 95%CI -0.2; 0.6). However, augmentation index was significantly higher in ACHD (standardized MD 1.6, 95%CI 0.8; 2.4).Conclusions:ACHD patients have impaired endothelial and microvascular function and increased arterial stiffness, factors that may be responsible for the increased adverse cardiovascular events in this population.

Circulation, Volume 150, Issue Suppl_1, Page A4145287-A4145287, November 12, 2024. BACKGOUND:Statins have shown benefits in the prognosis of patients with heart failure with reduced ejection fraction (HFrEF). However, the effects of statin in patients with heart failure with preserved ejection fraction (HFpEf) remains unclear. Therefore, we aim to perform an updated systematic review and propensity scores (PS) meta-analysis comparing statin with no statin therapy in this population.METHODS:We searched in PubMed, Embase, and Cochrane Library databases for studies examining the effect of statin use in patients with HFpEF. The primary outcome was (1) all-cause mortality, with secondary outcomes being (1) cardiovascular (CV) mortality and (3) heart failure (HF) hospitalization. We also performed a subgroup analysis for the primary outcome, comparing studies that used PS and studies that did not adjust the baseline covariates.RESULTS:We included in this meta-analysis a total of 17 studies. Our study encompassed 43,911 patients with HPpEF, of whom 19,142 (43.59%) received statin therapy. The mean age was 66.95 years, with a mean follow-up of 3.08 years. In the pooled analysis, statin was significantly associated with reduced all-cause mortality (HR 0.68; 95%CI 0.62-0.76; p

Circulation, Volume 150, Issue Suppl_1, Page A4147872-A4147872, November 12, 2024. Introduction:Both self-expanding (SEV) and balloon-expandable (BEV) valves are used in transcatheter aortic valve implantation (TAVI) for patients with severe aortic stenosis (AS) and small aortic annulus (SAA). This updated meta-analysis compares the efficacy and safety of SEV versus BEV in TAVI for these patients.Hypothesis:This study investigates whether SEV valves are hemodynamically and clinically superior to BEV valves in patients with small aortic annulus.Methods:PubMed, SCOPUS, and Cochrane Central databases were systematically searched for randomized and observational studies comparing SEV and BEV in TAVI for SAA patients. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model for clinical outcomes (all-cause mortality, stroke, permanent pacemaker implantation [PPI]) and hemodynamic parameters (mean gradient [MG], indexed effective orifice area [iEOA], moderate to severe prosthesis-patient mismatch [PPM], and paravalvular leak [PVL]).Results:A total of 21 studies involving 6,515 patients (58.4% treated with SEV) were included. SEV valves were associated with lower all-cause mortality (OR 0.75; 95% CI 0.60-0.95; p=0.014), lower MG (OR -4.44; 95% CI -5.48-3.39; p

Circulation, Volume 150, Issue Suppl_1, Page A4140224-A4140224, November 12, 2024. Background:In recent years, there has been a rise in the adoption of conservative approaches to managing patent ductus arteriosus (PDA) in preterm infants. Systematic appraisal of the clinical evidence supporting this approach is essential for guiding recommendations in clinical guidelines.Methods:A comprehensive search of MEDLINE (PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, spanning from inception to April 2024, was conducted to identify all relevant randomized controlled trials (RCTs) that evaluated conservative management of patent ductus arteriosus (PDA) in preterm infants. Conservative management was defined as approximately ≤25% open-label pharmacological treatment with ibuprofen, indomethacin, or paracetamol and/or ligation/endovascular closure. Our primary outcomes were the risk of all-cause mortality and bronchopulmonary dysplasia. We used RevMan 5.4 to pool risk ratios (RRs) under a random-effects model, ensuring a rigorous and reliable analysis.Results:Our review included 6 RCTs. There was no difference in the risk of mortality (RR 0.83; 95% CI: 0.64-1.08, I2= 0%) and BPD (RR 0.89; 95% CI: 0.76-1.03, I2= 22%) between the conservative management and active treatment groups. The rates of necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, sepsis, pulmonary hemorrhage, and the need for surgical ligation or transcatheter occlusion were similar between the two groups.Conclusions:The meta-analysis showed no difference in the risk of all-cause mortality, BPD, or other clinical outcomes between a strategy of conservative management compared to active treatment. These findings support a conservative approach for the management of PDA in preterm infants. Future studies should focus on cost-effectiveness analyses between the two approaches and investigate important subgroups, such as extremely preterm births.

Circulation, Volume 150, Issue Suppl_1, Page A4145901-A4145901, November 12, 2024. Introduction:Current guidelines recommend preprocedural fasting for at least 6 hours for solid food and 2 hours for clear liquids before cardiac transcatheter procedures. However, the supporting data are limited.Research Question:Does non-fasting impact (NF) patient safety and comfort compared to fasting (F) in transcatheter cardiac procedures?Aims:To compare the effects of fasting vs. non-fasting on patient outcomes in cardiac transcatheter procedures.Methods:We searched the Cochrane, Embase, and Medline databases for RCTs comparing fasting versus non-fasting states for cardiac transcatheter procedures. Risk ratios (RRs) and standardized mean difference (SMD) with 95% confidence intervals (CIs) were pooled for binary and continuous outcomes, respectively, using a random-effects model. Endpoints were hunger, thirst, incidence of aspiration, nausea/vomiting, acute kidney injury (AKI), length of stay, and patient satisfaction.Results:Our meta-analysis included 8 studies with 2,930 patients. Hunger sensation was significantly lower in the NF group (SMD -0.91; 95% CI: -1.71 to -0.11; P = 0.026; I2 = 96%; Figure 1A), with no difference in thirst. The incidence of aspiration (RR 2.20; 95% CI 0.29–17.02; P = 0.449; I2 = 0%; Figure 1B), nausea/vomiting (RR 1.09; 95% CI 0.67-1.78; P = 0.723; I2 = 0%), and AKI (RR 1.90; 95% CI 0.84–4.31; P = 0.126; I2 = 0%) were not significantly different between groups. Similarly, length of stay (MD -0.01 days; 95% CI -0.39 to 0.36; P = 0.940; I2 = 3%; Figure 2A), and patient satisfaction (SMD -0.74; 95% CI: -1.54 to -0.07; P = 0.073; I2 = 98%; Figure 2B) were also similar in both groups.Conclusions:Our study suggests a non-fasting strategy is a safe option before transcatheter cardiac procedures.

Circulation, Volume 150, Issue Suppl_1, Page A4138074-A4138074, November 12, 2024. Background:Various durations and de-escalation strategies of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention for patients presenting with acute coronary syndromes (ACS) have been reported in randomized controlled trials (RCTs). However, it remains uncertain whether the effect of these DAPT strategies is influenced by sex.Methods:PubMed and EMBASE were searched in May 2024. We included RCTs which investigated DAPT strategies for ACS patients comparing any de-escalation strategies such as short-term DAPT (≤6 months) followed by P2Y12inhibitor or aspirin monotherapy, unguided de-escalation from potent P2Y12inhibitors to low-dose potent P2Y12inhibitors or clopidogrel at one month, and guided de-escalation with platelet function tests, compared with standard duration DAPT (6-12 months). We conducted a systematic review and meta-analysis. The efficacy and safety of each DAPT strategy was compared between sexes, and relative hazard ratios (RHR) were calculated. The primary outcome was net adverse clinical events (NACE), defined as a composite of cardiovascular death, myocardial infarction, stroke, and major bleeding (BARC 3 or 5).Results:Eleven RCTs that enrolled 27,033 patients with ACS were included. De-escalation of antiplatelet therapy had a lower risk of NACE than standard duration DAPT for both female (HR, 0.73; 95% CI, 0.55-0.96;I2=32%) and male (HR, 0.85; 95% CI, 0.74-0.97;I2=23%). There were no significant differences in NACE between female and male patients randomized to de-escalation vs. standard duration DAPT (RHR, 0.84; 95% CI, 0.65-1.09 ;I2=0%) (Figure). Similarly, no significant differences were observed between female and male patients with respect to major adverse cardiovascular events (RHR, 0.75; 95% CI, 0.52-1.08;I2=0%) or major bleeding (RHR, 1.37; 95% CI, 0.85-2.21 ;I2=0%).Conclusion:In patients with ACS, de-escalation of antiplatelet therapy is safe and effective irrespective of sex.

Circulation, Volume 150, Issue Suppl_1, Page A4141750-A4141750, November 12, 2024. Background:The latest guidelines advocate for catheter ablation (CA) over standard medical therapy (SMT) for managing atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF). However, significant knowledge gaps exist regarding the effectiveness of CA vs. SMT in patients with heart failure with preserved ejection fraction (HFpEF).Methods:PubMed, Scopus, and Embase until February 2024 were systematically searched. Given the limited number of randomized studies, propensity score-matched observational studies comparing CA with SMT in AF patients with HFpEF were also included. The primary outcome was a composite endpoint of all-cause mortality and HF hospitalization.Results:Eight studies that enrolled 17,717 SMT and 2537 CA patients were included. CA was associated with a significantly lower risk of the composite endpoint of all-cause mortality and HF hospitalization (HR 0.69, 95% CI: 0.40-0.98). The risk of HF hospitalization (HR 0.48, 95% CI: 0.17-0.80), cardiovascular mortality (HR 0.27, 95% CI: -0.06-0.61), and AF recurrence (HR 0.53, 95% CI: 0.37-0.70) were also lower in the CA group.Conclusion:CA demonstrated significant cardiovascular morbidity and mortality benefits when compared to SMT in the HFpEF population.

Circulation, Volume 150, Issue Suppl_1, Page A4144674-A4144674, November 12, 2024. Introduction:While right ventricular pacing (RVP) is the conventional temporary pacing modality used for transcatheter aortic valve replacement (TAVR), this approach possesses inherent risks and procedural challenges. We aim to assess and compare safety and efficacy of left ventricular pacing (LVP) and RVP during TAVR and balloon aortic valvuloplasty (BAV).Methods:Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted in four databases from inception to December 15th, 2023. We included observational studies and clinical trials comparing LVP with RVP during TAVR and BAV procedures. The risk ratio (RR) with a 95% confidence interval (CI) was used to compare dichotomous outcomes, while continuous outcomes were reported in form of mean difference (MD).Results:Five studies involving 830 patients with RVP and 1577 with LVP were included. Short-term mortality was significantly higher in the RVP group (RR 2.32, 95% CI: [1.37-3.93], P = 0.002), as was the incidence of cardiac tamponade (RR 2.19, 95% CI: [1.11-4.32], P = 0.02). Subgroup analysis of the TAVR studies only revealed similar trends with higher short-term mortality in the RVP group (RR 1.99, 95% CI: [1.13-3.51], P-value = 0.02). LVP demonstrated shorter hospital stays (MD = 1.34 d, 95% CI: [0.90, 1.78], P